Twist Bioscience (TWST) PT Lowered to $40 at Barclays
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts TWST Hot Sheet
Price: $142.58 +1.63%
Rating Summary:
12 Buy, 3 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Rating Summary:
12 Buy, 3 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 17 | Down: 29 | New: 13
Join SI Premium – FREE
Barclays analyst Luke Sergott lowered the price target on Twist Bioscience (NASDAQ: TWST) to $40.00 (from $45.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Why the Next Edge in Antibody Discovery May Be What Labs Remember
- Notice of Proposed Derivative Settlement: Twist Bioscience Corporation
- Insulet Corporation (PODD) PT Raised to $200 at Jefferies
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
